| Literature DB >> 15542007 |
P David Charles1, Bimal B Padaliya, William J Newman, Chandler E Gill, Cassondra D Covington, John Y Fang, Stephanie A So, Michael G Tramontana, Peter E Konrad, Thomas L Davis.
Abstract
This study reports a retrospective analysis of 16 patients to determine changes in medication costs associated with deep brain stimulation of the bilateral subthalamic nucleus (DBS B-STN). Antiparkinsonian medication (APMED) costs were evaluated pre- and post-operatively at 1 and 2 years, based on prescribed dosages. After treatment with DBS, patients experienced a 32% reduction in APMED costs after 1 year and a 39% reduction after 2 years. Hypothetical projections of total potential savings are presented, accounting for increasingly complex medication regimens and medication cost inflation. DBS patients may experience a significant long-term reduction in the cost of their pharmacologic treatment.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15542007 DOI： 10.1016/j.parkreldis.2004.05.006
Source DB: PubMed Journal: Parkinsonism Relat Disord ISSN： 1353-8020 Impact factor: 4.891